Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says
Headline from Local News 8
By Deidre McPhillips, CNN (CNN) — Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly. In a head-to-head comparison of the two GLP-1 drugs, adults living with obesity or overweight who were taking Zepbound, the br…
Local News 8's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
By Deidre McPhillips, CNN (CNN) — Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly. In a head-to-head comparison of the two GLP-1 drugs, adults living with obesity or overweight who were taking Zepbound, the br…
Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical trial results. Zepound manufacturer Eli Lilly released results from their SURMOUNT-5 phase clinical trial on Wednesday which is the first time both GLP1s have been compared sid…
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, according results of the study released Wednesday.
People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical trial, Lilly said in a release Wednesday.
Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says | Since Then
